Latest Morphotek Inc. Stories
EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology products, today announced that they have entered into an evaluation and option agreement in which Morphotek will evaluate monoclonal antibodies targeting certain tumor-associated proteins. The agreement with CII provides Morphotek access to several of CII's...
EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease. Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a...
Antibody Targets Endosialin, a Protein Widely Expressed on Tumors and Tumor Blood Vessel Cells EXTON, Pa., June 9 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to study MORAb-004 in the treatment of patients with solid tumors. MORAb-004 targets endosialin, a protein expressed on cells associated with tumors and tumor blood vessel cells....
Agreement Underscores Morphotek's Commitment to the Development of Farletuzumab for Ovarian Cancer Agreement Highlights Lonza's Ability to Offer Specialty Development and Manufacturing Solutions EXTON, Pa. and BASEL, Switzerland, May 19 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, and Lonza Group Ltd jointly announced today that they have executed a manufacturing services agreement to support the development and manufacturing of a subset of...
ROCKVILLE, Md. and EXTON, Pa., March 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology that specifically target antigens discovered by HGS. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "The rapid...
EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure. "We are pleased that the...
EXTON, Pa., March 2 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma. The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma. The primary objective of the study is to assess the efficacy of MORAb-009 as combination therapy with the...
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, and Pivotal BioSciences, Inc., a privately held Los Angeles-based biotechnology company developing oncology products, today announced they have entered into an agreement in which Morphotek will access Pivotal BioSciences' LEC platform technology, developed by Dr. Alan Epstein, M.D., Ph.D, for the development of therapeutic monoclonal antibodies. The technology enhances the human immune system's ability to produce an...
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has opened clinical sites in the European Union (EU) as part of the company's MORAb-009 Phase II study. The study is evaluating MORAb-009, a monoclonal antibody to mesothelin, as a first-line treatment for patients with pancreatic cancer. The randomized, controlled, double-blinded trial will compare MORAb-009 plus gemcitabine with a placebo plus gemcitabine. Morphotek has currently qualified 33...
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the rights to a monoclonal antibody for a novel antigen identified by NCI researchers. Morphotek will apply its proprietary MORPHODOMA(R) antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer. "This agreement represents another important milestone in our...
